



(51) International Patent Classification:

A61K 39/395 (2006.01) *A61P 25/00* (2006.01)
C07K 16/22 (2006.01) *A61P 35/00* (2006.01)
G01N 33/53 (2006.01) *A61P 19/02* (2006.01)
C12N 15/68 (2006.01) *A61P 29/02* (2006.01)
C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2010/051960

(22) International Filing Date:

8 October 2010 (08.10.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12/576,522 9 October 2009 (09.10.2009) US

(71) Applicants (*for all designated States except US*): **AM-GEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). **MEDAREX, INC.** [US/US]; Route 206 & Province Line Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WILD, Kenneth, D.** [US/US]; 1604 Meander Drive, Simi Valley, CA 93065 (US). **TREANOR, James, J.s.** [GB/US]; 454 Upper Lake Road, Sherwood, CA 91361 (US). **HUANG, Haichun** [US/US]; 4329 Crestwood Street, Fremont, CA 94538 (US). **INOUE, Heather** [US/US]; 6733 Limonite Court, Carlsbad, CA 92009 (US). **ZHANG, Tie, J.** [US/US]; 5077 Via Camino, Thousand Oaks, CA 91320 (US). **MARTIN, Frank** [US/US]; 865 Fernhill Court, Newbury Park, CA 91320 (US).

(74) Agent: **MENSAH, Kwame, N.**; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Suite 3100, Chicago, IL 60606 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with information concerning one or more priority claims considered void (Rule 26bis.2(d))*

(54) Title: HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS

(57) Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.

